Not many cops go to work looking to shoot somebody because it's easier for them to get paid just for doing their job and hoping that nothing goes wrong. The lawyer for the Browns described this as case where the kid got killed for stealing cigars, which is a complete fabrication. That's what leads me to believe the cop is telling the truth plus the testimony of the majority of African American witnesses on the grand jury who more than likely would have wanted to indict this cop if he did something wrong.
even if therapies take 5 years to come to market, and I think it may happen before that in europe, investors will be looking ahead and buying shares in anticipation of where the share price will be in 5 years. nobody wants to buy after the horse is already out of the barn, so if you believe ocat will still be around and selling product in 5 years now is the time to buy. when ocat uplists, share price will go up fast because of institutional buying.
Might be referring to Neuralstem and possibly Verastem. They're both getting good results in clinical testing.
Neuralstem "In September, Jonathan D. Glass, MD, NSI-566 ALS site principal investigator at Emory University, presented long-term follow-up data of approximately 1,200 days on the Phase I trial, at the Annual Symposium on ALS of the Foundation Andre-Delambre, in Montreal. Dr. Glass reported that patients in the final safety cohort received a total of 15 injections of 100,000 cells treatments in both the lumbar and cervical regions of the spinal cord showed significant slowing of the progression of the symptoms of the disease as measured by the ALSFR-S scores. One patient showed functional improvement from pre-treatment baseline, which is maintained to present day. The other two patients are maintaining the same level of functionality as they had at the baseline."
The past 20 years of ACT history is typical of fits and starts getting new technology to point of acceptance and therapeutic relevance. Aapl hung around in the minor leagues for years, too, but for people that bought at the right time, they got high returns. If you buy OCAT going forward, you'll do better than if you bought 15 or 20 years ago, because now there is an increasing awareness of regenerative medicine that can lead to exponential increase in market value. Institutions will start loading up as soon as the technology is proven valid and before the company makes money. You have to make your bet on the Superbowl before it's played.
The 1 year trend is up both on the money flow and the volume for this stock, especially considering the reverse split and consequent dilution that occurred. Considering that reliable PR has it that people are recovering from a near state of blindness, we can expect to see considerable increases in share price, in spite of volatility which is endemic to the market. Also consider there are going to be an expanding range of therapeutic applications, for instance Dr. Atala in the NPR program mentioned heart and lung disease and other medical conditions. In fact every type of tissue in the body could benefit from this approach. Nothing goes up in a straight line, there is always programmed trading and speculators trying to knock the price down so they can pick up cheap shares and in fact it will be years before everyone with money to invest even finds out about this stock. Also you have scheduled sales of insider shares, why shouldn't they sell, they're going to keep getting options as the price increase so its just a form of income. It's no big deal when you already have a big salary and money invested.
I think I saw in one of the analyst's reports there is a mention that BLT may have to go to market again for more funds. So prescient investors may acting ahead of the trend. Having said that, this might be a real good time to buy more shares, because there could be some very some very important news generated from these trials.
That's a pretty big blunder on NPR saying that embryos are destroyed by this therapy. Also no mention there are many ways of obtaining stem cells other than embryonic stem cells. Would have been a good idea to mention at least something of Atala's credentials as well. "Anthony Atala, M.D. is the W.H. Boyce Professor and Director of the Wake Forest Institute for Regenerative Medicine, and Chair of the Department of Urology at Wake Forest School of Medicine in North Carolina. Regenerative medicine is "a practice that aims to refurbish diseased or damaged tissue using the body's own healthy cells."
I was reading an article that said the way Ebola infects cells is similar to the way HIV infects cells. Is it possible ddRNAi could be used as a therapy for Ebola as well as HIV?